This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

FRANK M. KAMER, MD
Beverly Hills, Calif

Arch Otolaryngol Head Neck Surg. 1988;114(10):1102-1103.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Since their discovery in 1949, cyanoacrylates have evoked great interest as being a possible ideal "tissue glue." Several different forms of these compounds have been developed in order to eliminate tissue toxicity. The first compound clinically tested was methyl-2-cyanoacrylate (Eastman 910 monomer). By 1970, the histotoxicity of this derivative became obvious, and it was considered unsafe for clinical trials. The same was found for isobutyl2-cyanoacrylate (Bucrylate). Attention was then turned toward a longer-chain monomer, butyl-2-cyanoacrylate (Histoacryl, Trihawk International, Montreal). Experimentation revealed Histoacryl to have a markedly reduced histotoxic effect on the tissues when compared with the smaller-chain monomers, methyl and isobutyl. Histoacryl has enjoyed widespread applications with uses including splenorenal anastomosis, temporary punctal occlusion of the lacrimal system, closure of upper eyelid blepharoplasties, and as an adhesive for onlay cartilaginous grafts.

This report describes the results of a six-month clinical trial conducted at the Lasky Clinic, Beverly Hills, Calif, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?